Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | MLN4924 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MLN4924 | Pevonedistat | MLN-4924 | Pevonedistat (MLN4924) binds and inhibits NEDD8, a ubiquitin-like protein, leading to inhibition of NFKB signaling, reduced transcription of target genes, and increased apoptosis in cancer cells with increased NFKB activity (PMID: 24634471, PMID: 29781056, PMID: 32721435). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
Unknown unknown | ovarian cancer | not applicable | MLN4924 | Preclinical | Actionable | In a preclinical study, MLN4924 demonstrated moderate efficacy in ovarian cancer cell lines and enhanced synergistic effects in combination with cisplatin or carboplatin (PMID: 23939375). | 23939375 |
Unknown unknown | Advanced Solid Tumor | not applicable | MLN4924 | Phase I | Actionable | In a Phase I trial, Pevonedistat (MLN4924) treatment resulted in stable disease in 74% (23/31) of patients with advanced solid tumors (PMID: 26423795). | 26423795 |
Unknown unknown | acute myeloid leukemia | not applicable | MLN4924 | Phase I | Actionable | In a Phase I trial, treatment with MLN4924 in patients with acute myeloid leukemia resulted in two patients acheiving a complete remission, five patients with partial remission, and 62% (34/55) of patients achieving stable disease (PMID: 28157218). | 28157218 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04175912 | Phase II | Carboplatin + MLN4924 + Paclitaxel MLN4924 | Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver | Suspended | USA | 0 |
NCT02610777 | Phase II | Azacitidine MLN4924 | An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) | Active, not recruiting | USA | CAN | 10 |
NCT01814826 | Phase I | MLN4924 Azacitidine | Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | Completed | USA | 0 |
NCT02122770 | Phase I | Paclitaxel Docetaxel Itraconazole Carboplatin MLN4924 Fluconazole | Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03319537 | Phase Ib/II | MLN4924 Cisplatin + MLN4924 + Pemetrexed Disodium | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | Recruiting | USA | 0 |